NEULANDLAB news

• 03-Nov-2026 21:49:38

  NEULAND LABORATORIES Q2 FY27 CONCALL: MAINTAINS H2 FY27 GROWTH OUTLOOK & EXPECTS FY28 GROWTH; PEPTIDE PPQ REVENUE TARGETED IN 6–9 MONTHS, COMMERCIAL REVENUE IN 1.5–2 YEARS & ₹1,700–1,800 CR THREE-YEAR CAPEX UNDER REVIEW

  NEULAND LABORATORIES Q2 FY27 CONCALL: MAINTAINS H2 FY27 GROWTH OUTLOOK & EXPECTS FY28 GROWTH; PEPTIDE PPQ REVENUE TARGETED IN 6–9 MONTHS, COMMERCIAL REVENUE IN…

• 03-Nov-2026 15:51:06

  NEULAND LABORATORIES Q2 FY27 ; NET PROFIT DOWN 47% AT ₹52 CR (YOY), DOWN 65% (QOQ)

  REVENUE DOWN 13% AT ₹450 CR (YOY), DOWN 30% (QOQ) EBITDA DOWN 37% AT ₹98 CR (YOY), DOWN 56% (QOQ) MARGINS AT 21.7% VS 30.2% (YOY), 34.7% (QOQ)

• 03-Nov-2026 15:49:52

  NEULAND LABORATORIES : EXPANSION VIA LAND ACQUISITION

  • Approved capital expenditure of ₹47.1 crores towards acquisition of land parcel at Domadugu Village, Sangareddy District, Telangana. • Investment required is…

• 14-Oct-2026 21:44:36

  NEULANDLAB: US FDA ISSUES EIR FOR UNIT 3, INSPECTION CLOSED

  US FDA concluded inspection conducted Aug 10-14, 2026 at Unit 3 facility in Sangareddy District as closed.

• 15-Sept-2026 10:27:44

  NEULAND LABORATORIES : EXPANSION IN PEPTIDE MANUFACTURING

  NEULAND LABORATORIES : EXPANSION IN PEPTIDE MANUFACTURING

← Back to feed